Results 41 to 50 of about 11,464,348 (142)
ABSTRACT Combined use of S‐ICD and LP provides an effective alternative for patients requiring defibrillation and pacing while avoiding transvenous leads. This strategy is particularly valuable for patients with a high risk of infection, though careful consideration must be given to minimizing potential device–device interactions.
ZhaoWei Zhou +3 more
wiley +1 more source
Introduction: T-wave oversensing (TWOS) is generally seen in patients with hypertrophic cardiomyopathy (HCM) and is a rare cause of inappropriate implantable cardioverter defibrillator (ICD) shocks. TWOS rarely causes pacemaker dysfunction.
Filiz Kizilirmak +4 more
doaj +1 more source
S‐ICD therapy demonstrated favorable mid‐term safety and efficacy in pediatric patients, with durable sensing performance and a low incidence of device‐related infection. ABSTRACT Background The subcutaneous implantable cardioverter‐defibrillator (S‐ICD) avoids transvenous leads and is a promising option for sudden cardiac death (SCD) prevention in ...
Hitoshi Mori +76 more
wiley +1 more source
The subcutaneous implantable cardioverter-defibrillator (S-ICD) is a novel technology with proven efficacy in sudden cardiac death prevention; however, there is a lack of long-term safety data.
Maria João Sousa, MD, Tim Betts, MD
doaj +1 more source
Abstract Purpose Motion of individuals carrying active implantable medical devices (AIMDs), such as pacemakers (PMs) and implantable cardioverter defibrillators (ICDs), within the spatially varying static magnetic field in and around magnetic resonance imaging (MRI) systems can induce electromotive forces (EMFs) in conductive leads.
Valentina Hartwig +5 more
wiley +1 more source
Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is recognized as a viable alternative to the transvenous ICD. The safety and efficacy of this device has been demonstrated in Western countries, but studies with S-ICD ...
Nobuhiro Nishii, MD +10 more
doaj +1 more source
Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is effective in preventing sudden cardiac death. Compared with transvenous ICDs, S-ICDs have a lower rate of inappropriate shocks (IASs) for supraventricular arrhythmias, but ...
Yuji Ishida, MD, PhD +10 more
doaj +1 more source
Implantable Cardioverter‐Defibrillators in Children: A 14‐Year Population‐Based Study
Nationwide pediatric ICD cohort from Slovakia illustrating incidence, indications, shock outcomes, and device‐related adverse events, highlighting the predominance of secondary prevention and the clinical burden of inappropriate shocks and major complications.
Marko Bjeloševič +4 more
wiley +1 more source
Hyperkalemia-Induced T Wave Oversensing in an Implantable Cardioverter Defibrillator
A 66-year-old female with end-stage renal disease and heart failure with reduced ejection fraction, status post implantable cardioverter defibrillator (ICD) presented to the emergency department with dizziness and fatigue. An electrocardiogram showed sinus rhythm, complete atrioventricular block, and ventricular paced rhythm at 30 beats per minute (bpm)
Gonzalez, Ariel +3 more
openaire +2 more sources
A graphical summary of the mechanism underlying the underestimation of a prolonged pause episode by an implantable cardiac monitor (ICM). This case illustrates that ICM episode summaries may underestimate clinically significant pauses, underscoring the importance of electrogram review and remote monitoring for accurate diagnosis.
Ryo Takahashi +2 more
wiley +1 more source

